Canada and Ontario’s life sciences sector has been leading unprecedented efforts to respond to the COVID-19 crisis. However, our sector faces an impending challenge – the planned implementation of the Government of Canada’s amendments to the Patented Medicines Regulations. These new regulations threaten to divert our sector’s attention and resources away from…
Uncategorized
Canada’s life sciences sector has been at the forefront of our country’s response to the COVID-19 pandemic. Our sector also has significant potential to drive Canada’s economic recovery and build up our resilience to future health challenges. In this context, life sciences sector stakeholders remain deeply concerned about the federal…
In these unprecedented times, access to new medicines and vaccines has never been more important. However, new federal drug pricing regulations changing the Patented Medicine Prices Review Board (PMPRB) are hurting Canadians’ access to new life-saving medicines and vaccines. According to a recent Research Etc. survey of 43 pharmaceutical leaders:…
Toronto, Ontario – LSO remains concerned by today’s release of the final PMPRB guidelines implementing the federal government’s patented medicine price controls. The final guidelines create a highly risky and uncertain pathway for commercializing new medicines and vaccines in Canada. LSO President and CEO Jason Field wants to ask the…
May 22, 2014 (Toronto) – A successful innovative life sciences sector is critical to growing the economy, delivering better and sustainable healthcare, and improving the quality of life for all Ontarians. As Ontario heads towards the June 12th election, a group of leading innovative life sciences and economic organizations is…